I-Mab Review Phase 1 ESMO Results for CLDN 18.2 Ab, Givastomig, in Development for Gastric Cancers and Other Advanced Solid Tumors
About The Event
Join us in-person for the I-Mab KOL event featuring Geoffrey Ku, MD (Memorial Sloan Kettering Cancer Center) who will discuss the clinical data presented at the European Society for Medical Oncology (ESMO) meeting from the Phase 1 study evaluating Givastomig (TJ-CD4B) in patients with advanced solid tumors, including gastroesophageal cancer.
Givastomig is a unique, bispecific antibody that integrates Claudin 18.2 as a tumor engager and 4-1BB as a conditional T-cell activator.
I-Mab’s Chief Medical Officer, John Hayslip, MD, will provide an overview of next steps for the program, including sharing the interim Phase 1 monotherapy dose expansion data and the plan to initiate a new dose expansion study, in combination with chemotherapy, in H1 2024.
A live question and answer session with I-Mab’s management team will follow the formal presentations.